Jonathan R. Fromm
YOU?
Author Swipe
View article: 31 Flow cytometry of skin provides valuable diagnostic information while representing an under-recognized paucicellular specimen type
31 Flow cytometry of skin provides valuable diagnostic information while representing an under-recognized paucicellular specimen type Open
Background Cutaneous lymphomas remain notoriously difficult to diagnose despite integration of multiple ancillary studies, including PCR analysis of the gamma chain of the T cell receptor (TRG) for clonality. Although widely available, flo…
View article: A practical approach to panel design, validation, and interpretation for the evaluation of <scp>T</scp> ‐cell neoplasms by flow cytometry
A practical approach to panel design, validation, and interpretation for the evaluation of <span>T</span> ‐cell neoplasms by flow cytometry Open
The diagnosis of T‐cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This “Best Practice” manuscript provides a pra…
View article: Daratumumab and isatuximab differentially affect <scp>CD38</scp> detection on plasma cells in myeloma: Anti‐<scp>CD38</scp> nanobody (clone <scp>JK36</scp>) and <scp>CD319</scp> combination improve flow cytometric identification of plasma cells after targeted therapies
Daratumumab and isatuximab differentially affect <span>CD38</span> detection on plasma cells in myeloma: Anti‐<span>CD38</span> nanobody (clone <span>JK36</span>) and <span>CD319</span> combination improve flow cytometric identification of plasma cells after targeted therapies Open
Summary Inclusion of daratumumab and isatuximab in therapeutic regimens has improved outcomes in multiple myeloma patients. As these agents block CD38 detection, they may result in difficulties in flow cytometric (FC) identification of pla…
View article: Dual <scp>PD</scp>‐1 and <scp>CTLA4</scp> Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers
Dual <span>PD</span>‐1 and <span>CTLA4</span> Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers Open
Background No standard systemic therapy exists for recurrent/metastatic salivary gland cancer (R/M SGC). We explored the safety and activity of nivolumab and ipilimumab with palliative hypofractionated radiation (XRT) in this population. M…
View article: Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas
Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas Open
Multi-parametric flow cytometry is a powerful diagnostic tool that permits rapid assessment of cellular antigen expression to quickly provide immunophenotypic information suitable for disease classification. This chapter describes the clas…
View article: CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells Open
Multiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuximab, which can kill MM cells by inducing c…
View article: Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up Open
View article: MEF2B is the ideal immunohistochemical marker to highlight neoplastic LP cells in nodular lymphocyte‐predominant Hodgkin lymphoma
MEF2B is the ideal immunohistochemical marker to highlight neoplastic LP cells in nodular lymphocyte‐predominant Hodgkin lymphoma Open
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a tumor composed of scattered germinal center (GC) derived large neoplastic B-cells with multilobulated nuclei (LP cells) in a background of abundant reactive B- and T-cells and hi…
View article: Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia Open
This study reports the pharmacologic effects of isatuximab, a CD38 mAb, on T- and B-cell acute lymphoblastic leukemia (ALL). We analyzed CD38 expression in 50-T-ALL and 50 B-ALL clinical samples, and 16 T-ALL and 11 B-ALL cell lines. We pr…
View article: Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia Open
This study reports the pharmacologic effects of isatuximab, a CD38 mAb, on T- and B-cell acute lymphoblastic leukemia (ALL). We analyzed CD38 expression in 50-T-ALL and 50 B-ALL clinical samples, and 16 T-ALL and 11 B-ALL cell lines. We pr…
View article: Supplementary Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Supplementary Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia Open
Supplementary data
View article: Supplementary Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Supplementary Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia Open
Supplementary data
View article: Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer Open
Supplementary Material
View article: Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer Open
Supplementary Material
View article: Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer Open
Supplement Figure 1: Synergistic cytotoxic effect of pembrolizumab combined with vorinostat in HNSCC tissue slice culture. HNSCC slices (250 ï�m) were cultured and treated with 20 ï�g/ml of isotype control antibody IgG4 or pembrolizumab,…
View article: Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer Open
Purpose:This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC).Patients and Methods:Patients with progressing incurable HN and S…
View article: Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer Open
Purpose:This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC).Patients and Methods:Patients with progressing incurable HN and S…
View article: Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer Open
Supplement Figure 1: Synergistic cytotoxic effect of pembrolizumab combined with vorinostat in HNSCC tissue slice culture. HNSCC slices (250 ï�m) were cultured and treated with 20 ï�g/ml of isotype control antibody IgG4 or pembrolizumab,…
View article: Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors Open
Background Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint in…
View article: Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat
Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat Open
Background Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorino…
View article: Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL Open
Patients with indolent B-cell non-Hodgkin lymphoma (iNHL) generally require treatment but experience normal survival, emphasizing the need for simpler, safer therapies. Proteasome inhibitors target aberrant signaling pathways within iNHL a…
View article: 19 Peripheral lymphocytes and lactate dehydrogenase correlate with improved response and survival in head and neck cancer treated with immune checkpoint inhibitors
19 Peripheral lymphocytes and lactate dehydrogenase correlate with improved response and survival in head and neck cancer treated with immune checkpoint inhibitors Open
Background Little is known regarding peripheral blood biomarkers (PBBMs) for oncologic outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). We explored associa…
View article: P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry Open
Background: Classic Hodgkin lymphoma (CHL) is a highly treatable lymphoid malignancy, characterized by rare neoplastic Hodgkin Reed–Sternberg cells (HRS-cells) embedded in a prominent reactive infiltrate. Despite current therapies, about 2…
View article: Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8<sup>+</sup>T-cells despite immune checkpoint signaling
Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8<sup>+</sup>T-cells despite immune checkpoint signaling Open
These data may explain the failure of single-agent immune checkpoint inhibitors in the treatment of DLBCL. Accordingly, functional differences of CD8+ T-cells between FL and DLBCL may inform future therapeutic targeting strategies.
View article: Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures
Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures Open
Background: Standard chemoimmunotherapy for first-line treatment of follicular lymphoma (FL) achieves high rates of disease control but is not curative and carries significant toxicities including prolonged immunosuppression that may atten…
View article: Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia Open
This study reports the pharmacologic effects of isatuximab, a CD38 mAb, on T- and B-cell acute lymphoblastic leukemia (ALL). We analyzed CD38 expression in 50-T-ALL and 50 B-ALL clinical samples, and 16 T-ALL and 11 B-ALL cell lines. We pr…
View article: Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study Open
View article: De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning
De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning Open
Objectives Automated classification of flow cytometry data has the potential to reduce errors and accelerate flow cytometry interpretation. We desired a machine learning approach that is accurate, is intuitively easy to understand, and hig…
View article: Creating virtual H&E images using samples imaged on a commercial CODEX platform
Creating virtual H&E images using samples imaged on a commercial CODEX platform Open
Multiparametric fluorescence imaging via CODEX allows the simultaneous imaging of many biomarkers in a single tissue section. While the digital fluorescence data thus obtained can provide highly specific characterizations of individual cel…
View article: <i>De novo</i> identification and visualization of important cell populations for classic Hodgkin lymphoma using flow cytometry and machine learning
<i>De novo</i> identification and visualization of important cell populations for classic Hodgkin lymphoma using flow cytometry and machine learning Open
Objectives Automated classification of flow cytometry data has the potential to reduce errors and accelerate flow cytometry interpretation. We desired a machine learning approach that is accurate, intuitively easy to understand, and highli…